As of January 22, 2025, Trevi Therapeutics (TRVI) has a market cap of $0.34 billion USD. According to our data, Trevi Therapeutics is ranked No.6552 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.34 B |
-8.25%
|
Dec 31, 2024 | $0.37 B |
207.46%
|
Dec 29, 2023 | $0.12 B |
-30.57%
|
Dec 30, 2022 | $0.17 B |
146.80%
|
Dec 31, 2021 | $69.88 M |
-67.69%
|
Dec 31, 2020 | $0.22 B |
-35.47%
|
Dec 31, 2019 | $0.34 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Cara Therapeutics
CARA
|
$21.85 M |
0.000 M
|
USA
|
Intra-Cellular Therapies
ITCI
|
$13.51 B |
-0.000 M
|
USA
|
Corbus Pharmaceuticals
CRBP
|
$0.14 B |
-0.000 M
|
USA
|
Pacira Biosciences
PCRX
|
$1.04 B |
-0.000 M
|
USA
|
Heron Therapeutics
HRTX
|
$0.25 B |
0.000 M
|
USA
|
Collegium Pharmaceutical
COLL
|
$1.05 B |
0.000 M
|
USA
|
Assertio Therapeutics
ASRT
|
$77.34 M |
-0.000 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.17 B |
0.000 M
|
USA
|
Supernus Pharmaceuticals
SUPN
|
$2.11 B |
-0.000 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Market Cap | = | TRVI Stock Price | * | TRVI Shares Outstanding |
= | $3.78 | * | 89.37 M | |
= | $0.34 B |